Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab

FRIDAY, July 15, 2022 -- For treatment of diabetic macular edema involving the center of the macular, two-year outcomes are similar for those treated with aflibercept monotherapy and with bevacizumab first then a switch to aflibercept in cases of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news